Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.50 |
| ▸ | MTTP | P55157 | 8/20 | 0.49 |
| ▸ | APOB | P04114 | 1/20 | 0.47 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.43 |
| ▸ | MICA | Q29983 | 1/20 | 0.43 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4237299 | 0.90 | CHRNB2 (0.54) | CHRM4GAACHRNB2CHRNA4 | |
| SCHEMBL4245976 | 0.79 | DRD2 (0.58) | DRD2DRD4CHRM4BCHE | |
| SCHEMBL3731091 | 0.78 | DRD4 (0.68) | DRD2DRD4CHRM4MTTPSIGMAR1 | |
| SCHEMBL4242462 | 0.77 | DRD2 (0.43) | DRD2DRD4 | |
| SCHEMBL2589154 | 0.76 | HIF1A (0.59) | DRD2DRD4CHRM4MTTPAPOB | |
| SCHEMBL4189224 | 0.75 | GRIN2B (0.48) | DRD2DRD4SIGMAR1 | |
| SCHEMBL4246862 | 0.75 | ALDH1A1 (0.50) | DRD2DRD4GAA | |
| SCHEMBL4188612 | 0.73 | CHRM3 (0.43) | — | |
| SCHEMBL4190801 | 0.73 | CHRM3 (0.43) | — | |
| SCHEMBL2588205 | 0.73 | HIF1A (0.64) | MTTPAPOBGAAHIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | DRD2 563/4885DRD4 1807/4885CHRM4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.